On June 18, 2025, Prothena Corp announced a 63% workforce reduction to cut operating costs following the decision to stop developing birtamimab, expecting to incur $16 to $20 million in severance and related costs. Key executives, including the Chief Regulatory Officer and Chief People Officer, will also depart, effective August 1, 2025.